Latest Healthcare News

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Clarity Pharmaceuticals has partnered with SpectronRx to manufacture and distribute its lead prostate cancer diagnostic, Cu-64 SAR-bisPSMA, at commercial scale across the US. This agreement sets the stage for a seamless launch pending FDA approval.

Patrys Limited has formalized the redundancy of CEO Dr James Campbell, with a $535,877 payout partly converted into shares pending shareholder approval. Dr Campbell will continue as a non-executive director.

4DMedical has renewed and expanded its contract with Stanford University’s 3DQ Lab to include its innovative CT – VQ™ imaging technology ahead of FDA clearance, marking a significant step in its U.S. market expansion.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

Mayne Pharma rejects Cosette Pharmaceuticals’ claims of valid termination of their scheme deal, setting the stage for a September court showdown while urging shareholders to back the scheme in June.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.